Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group

BACKGROUND: We evaluated real-world clinical outcomes and toxicity data and assessed treatment-related costs in patients with advanced breast cancer who received treatment with cyclin-dependent kinase inhibitors (CDKi). PATIENTS AND METHODS: We conducted a prospective–retrospective analysis of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Fountzilas, Elena, Koliou, Georgia-Angeliki, Vozikis, Athanassios, Rapti, Vassiliki, Nikolakopoulos, Achilleas, Boutis, Anastasios, Christopoulou, Athina, Kontogiorgos, Ioannis, Karageorgopoulou, Sofia, Lalla, Efthalia, Tryfonopoulos, Dimitrios, Boukovinas, Ioannis, Rapti, Cleopatra, Nikolaidi, Adamantia, Karteri, Sofia, Moirogiorgou, Evangelia, Binas, Ioannis, Mauri, Davide, Aravantinos, Gerasimos, Zagouri, Flora, Saridaki, Zacharenia, Psyrri, Amanda, Bafaloukos, Dimitrios, Koumarianou, Anna, Res, Eleni, Linardou, Helena, Mountzios, Giannis, Razis, Evangelia, Fountzilas, George, Koumakis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437702/
https://www.ncbi.nlm.nih.gov/pubmed/32817060
http://dx.doi.org/10.1136/esmoopen-2020-000774

Ejemplares similares

Ejemplares similares